NasdaqGS:KRYSBiotechs
Is Krystal Biotech (KRYS) Too Expensive After A 440% Return?
Krystal Biotech’s stock has delivered a very large 439.7% return over the past five years, yet its current checks lean expensive, with a low value score and the market multiples suggesting investors are paying a premium for that track record.
Over five years, shareholders have seen a 439.7% return, which puts extra focus on whether today’s price still reflects a reasonable entry point.
Expectations for Krystal Biotech’s future revenue and cash flow can support a premium valuation, but any...